NCAM1 and cancer: CD56–chimeric antigen receptor T-cell therapy which has already shown promising results in the pre-clinical studies in other cancers could be used in the treatment of patients with a high CD56 expression in the tumor tissue who had shown disease recurrence with poor response to chemotherapy and radiotherapy (e.g. UESL case 6 in this study) [32].